Product nameHuman Apolipoprotein AI ELISA Kit (APOA1)
See all Apolipoprotein A I kits
Intra-assay Sample n Mean SD CV% Overall 5.1% Inter-assay Sample n Mean SD CV% Overall 10%
Sample typeSerum, Plasma
Range0.313 µg/ml - 10 µg/ml
Assay time3h 00m
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Apolipoprotein AI Human (APOA1) in vitro competitive ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Apolipoprotein AI levels in plasma and serum.
An Apolipoprotein AI specific antibody has been precoated onto 96-well plates and blocked. Standards or test samples are added to the wells and subsequently biotinylated Apolipoprotein AI is added and then followed by washing with wash buffer. Streptavidin-Peroxidase Complex is added and unbound conjugates are washed away with wash buffer. TMB is then used to visualize Streptavidin-Peroxidase enzymatic reaction. TMB is catalyzed by Streptavidin-Peroxidase to produce a blue color product that changes into yellow after adding acidic stop solution. The density of yellow coloration is inversely proportional to the amount of Apolipoprotein AI captured in plate.
Get results in 90 minutes with Human Apolipoprotein AI ELISA Kit (ab189576) from our SimpleStep ELISA® range.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.
Storage instructionsStore at -20°C. Please refer to protocols.
Components 1 x 96 tests 100X Streptavidin-Peroxidase Conjugate 1 x 80µl 10X Diluent N Concentrate 1 x 30ml 1X Biotinylated Human Apolipoprotein AI (Lyophilized) 2 vials 20X Wash Buffer Concentrate 1 x 30ml Apolipoprotein AI Microplate (12 x 8 well strips) 1 unit Apolipoprotein AI Standard 1 vial Chromogen Substrate 1 x 8ml Sealing Tapes 3 units Stop Solution 1 x 12ml
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
FunctionParticipates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
Tissue specificityMajor protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease.
Involvement in diseaseHigh density lipoprotein deficiency 2
High density lipoprotein deficiency 1
APOA1 mutations may be involved in the pathogenesis of amyloid polyneuropathy-nephropathy Iowa type, also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III (PubMed:3142462 and PubMed:2123470). The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis.
Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
Met-110 and Met-136 are oxidized to methionine sulfoxides.
Phosphorylation sites are present in the extracellular medium.
- Information by UniProt
- ApoA I
SimpleStep ELISA kits
ab108804 has been referenced in 6 publications.
- Aguirre-Portolés C et al. ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone. Mol Oncol 12:1735-1752 (2018). PubMed: 30098223
- Wang Y et al. The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus. Lipids Health Dis 15:64 (2016). PubMed: 27015844
- Lin Q et al. Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease. Drug Des Devel Ther 9:5421-31 (2015). ELISA . PubMed: 26491253
- Steffensen LB et al. Disturbed Laminar Blood Flow Vastly Augments Lipoprotein Retention in the Artery Wall: A Key Mechanism Distinguishing Susceptible From Resistant Sites. Arterioscler Thromb Vasc Biol 35:1928-35 (2015). PubMed: 26183617
- Guo Y et al. Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest 125:3819-30 (2015). PubMed: 26368306
- Wang Q et al. Serum apolipoprotein A-1 quantification by LC-MS with a SILAC internal standard reveals reduced levels in smokers. Bioanalysis 7:2895-911 (2015). PubMed: 26394123